“I remain very confident in our expectation for an acceleration in growth in the second half.”

In context

“s talking to the leader of that business yesterday—they have strategies to do better than that, with the second half higher than the first, consistent with what we have historically done. The team has done a very good job navigating VBP in China and continuing to drive growth in other parts of the business. In China, about 80% of our portfolio has gone through VBP. You will probably hear about new waves of VBP like a fertility VBP or a cancer VBP, and we have very little share in those segments. I do not want to say we are past the eye of the hurricane, but it seems like the teams have stabilized China, and the other businesses continue to perform the way they have historically performed. Just before we end the call, I would like to reiterate my comments at the end of my prepared remarks. I remain very confident in our expectation for an acceleration in growth in the second half. We know what the drivers are, we know where the accelerations are, we know where we need to improve execution, and we are laser focused on executing on them. Thank you all for joining us today. Michael Comilla: Thank you, operator. Thank you all for your questions. This now concludes Abbott Laboratories' conference call. A webcast replay of this call will be available after 11 AM Central Time today on our website at abbott.com. Thank you for joining us today. Operator: Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.”